A study on staging bone scans in newly diagnosed prostate cancer

Urologia Internationalis

Volumn 76, Issue 3, 2006, Pages 209-212

  Ayyathurai, R ^a,c   Mahapatra, R ^a   Rajasundaram, R ^a   Srinivasan, V ^a   Archard, N P ^b   Toussi, H ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

^b Department of Psychiatry of Learning Disability   (United Kingdom)

^c PRINCESS OF WALES HOSPITAL   (United Kingdom)

Author keywords

Bone metastases; Bone scan; Gleason scoring; Prostate cancer; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BIOPSY; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SAFETY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 33645653815     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091620     Document Type: Review

References (17)

1. Cancer registrations in England 2001. www.statistics.ga.uk.
2. Majeed A, Babb P, Jones J, Quinn M: Trends in prostate cancer incidence, mortality and survival in England and Wales 1971-1998. BJU Int 2000;85:1058-1062.
3. Kirby R: Early Prostate Cancer. Comprehensive Urology, ed 1. St Louis, Mosby, 2001.
4. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, Mettlin C: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982;127:928-934.
5. Whitmore W: National history and staging of prostate cancer. Urol Clin North Am 1984;11:209.
6. Lin K, Szabo Z, Chin BB, Civelek AC: The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999;24:579-582.
7. O'Sullivan JM, Cook GJ: A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002;46:152-159.
8. NICE: Improving outcomes in urological cancer. NICE, 2002.
9. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP: Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003;92:685-689.
10. EUA: EUA Guidelines. European Urological Association, 2005.
11. BAUS: Guidelines on management of prostate cancer. BJU Int 1999;84:987-1014.
12. Buckwalter JA, Brandser EA: Metastatic disease of the skeleton. Am Fam Physician 1997;55:1761-1768.
13. Pirtskhalaishvili G, Hrebinko RL, Nelson JB: The treatment of prostate cancer: an overview of current options. Cancer Pract 2001;9:295-306.
14. Koch MO, Miller DA, Butler R, Lebos L, Collings D, Smith JA Jr: Are we selecting the right patients for treatment of localized prostate cancer? Results of an actuarial analysis. Urology 1998;51:197-202.
15. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G: Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33:376-381.
16. Chan TY, Partin AW, Walsh PC, Epstein JI: Prognostic significance of Gleason score 3 + 4 versus Gleason score 4 + 3 tumor at radical prostatectomy. Urology 2000;56:823-827.
17. Lau WK, Blute ML, Bostwick DG, Weaver AL, Sebo TJ, Zincke H: Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol 2001;166:1692-1697.